Seeking Alpha

Infinity Pharmaceuticals (INFI) +8.6% after Morgan Stanley initiates coverage with an Overweight...

Infinity Pharmaceuticals (INFI) +8.6% after Morgan Stanley initiates coverage with an Overweight rating and a price-target of $47. "Infinity's wholly-owned early stage IPI-145 for blood cancers has shown positive early data and is on track to figure significantly in an emerging BCR drug class with multi-billion dollar potential. 2013 holds multiple catalysts to further validate IPI-145's efficacy/safety," firm says.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector